Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChronIA trial of morning versus evening tofacitinib XR dosing in inflammatory arthritis
NL-OMON52175Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib in autoimmune arthritis, rheumatoid arthritis (RA) and psoriatic arthritis (PsA) (2 arms), sponsored by Erasmus MC. Started Jun 2022; status: recruiting.
02
Drugs
03
Conditions
autoimmune arthritisrheumatoid arthritis (RA)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON52175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52175.